Ancestry.com DNA LLC

Pfizer is enlisting another Flagship startup to help it create new obesity medicines. After June’s ProFound Therapeutics tie-up , Pfizer will work with the incubator’s Ampersand Biomedicines in the hunt for new biologics for obesity. The New York pharmaceutical company is also tapping into Flagship-founded Montai Therapeutics to find new small molecules for potentially treating lung cancer, the companies said Wednesday morning. The two pacts are part of Pfizer’s broader alliance with the Cambridge, MA-based Flagship, which recently reeled in about $3.6 billion in new funds as pharma partnerships become a “ bigger and bigger deal .” Pfizer has had an uneven few years in obesity, particularly with its danuglipron program . Last month, it revealed more details about its other early-stage bets: a GIP antagonist and a once-daily oral GLP-1. Ampersand hopes to help Pfizer create obesity treatments that go to a specific site in the body, rather than hitting healthy tissues or cells, so as to avoid side effects — like muscle loss and gastrointestinal concerns — and to make the drugs more potent. The startup, which emerged with $50 million in March 2023, uses computational methods to find “addresses” for drugs to go to and then creates an “actuator” to carry out the therapeutic function, Flagship general partner Avak Kahvejian told Endpoints News last year. In January, it bought antibody discovery tech startup AbCheck, an Affimed subsidiary, for $6 million. “We have addresses in virtually every tissue in the body, so you could think about virtually any disease,” CEO Jason Gardner said in an interview. Ampersand will likely make multiple other industry collaborations, he said, and it could form more tie-ups around obesity. It’s early days with the Pfizer partnership, and Gardner declined to disclose the specific pathway tissue that they’re looking at. Flagship’s work in obesity has also attracted the attention of Novo Nordisk. Its companies Metaphore Biotechnologies and Omega Therapeutics have both formed partnerships with the Danish drugmaker. In cancer, Pfizer’s new partnership with Montai will look at mechanisms that lead to lung cancer cell growth and find new small molecules that can potentially be turned into therapies. Pfizer has made oncology a core focus following its $43 billion Seagen acquisition last year. Montai emerged with $50 million in December 2022 and a high-profile CEO, Margo Georgiadis, who previously led Google’s Americas division and steered Ancestry.com to a nearly $5 billion exit to Blackstone. The startup scours through molecules already consumed by humans via foods, supplements and herbal medicines. Its computational tools have brought together nearly 200 million so-called “Anthromolecules” and their derivatives, Georgiadis said. The company’s name means “climbing mountains with AI,” she said. Georgiadis said in an interview that the company is trying to “create the first machine learning that enables us to decode that language of chemistry and how it connects to our biology.” “By doing that, it enables us to take advantage of this unbelievably rich and diverse chemistry set that pharma had kind of put to the side,” she said. “It’s how drug development started. It’s a super-proven source of drugs, but it was perceived as complex, hard to make, the challenges with polypharmacology.” Montai was working on a small molecule agonist for an undisclosed pathway in inflammation and immunology when Pfizer realized an antagonist of that pathway could be applied in lung cancer, Georgiadis said. The 65-employee company has created an internal pipeline of nine I&I therapies that are transcription factors and biologic replacements in dermatology, gastrointestinal and respiratory diseases, she said. The company is “developing partnerships” with more companies, Georgiadis said, as Montai’s work applies across immunology, oncology, neuro-inflammation and other areas.

DUBLIN--( BUSINESS WIRE )--The "Human Gene Sequencing Markets, Strategies & Trends - Forecasts by Application, by Technology, by Workflow, by Product, and by Country, with Executive and Consultant Guides - 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Will all newborns receive genetic testing at birth? What segments are growing fastest? Where are the opportunities now that sequencing has gone mainstream? The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out for five years. The report includes detailed breakouts for 14 countries and 5 regions. Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years. Scope of the Report The Global Market for Human Genome Sequencing Global Market Overview by Country Global Market by Application - Overview Global Market by Technology - Overview Global Market by Workflow - Overview Global Market by Product - Overview Market Sizes by Application Hereditary Gene Sequencing Market NIPT Gene Sequencing Market Oncology Market Psychology Market WGES Gene Sequencing Market Pharmacogenomics Market DTC Gene Sequencing Market Research Gene Sequencing Market Other Application Market Market Sizes by Technology Sanger Sequencing Market NGS/2G Market 3G/Long Market Other Technology Market Market Sizes by Workflow Sequencing Market Sample Prep Market Analysis Market Market Sizes by Product Instruments Market Consumables Market Software & Services Market Vision of the Future of Human Gene Sequencing Key Topics Covered: 1 Market Guides 1.1 Human Gene Sequencing Markets - Strategic Situation Analysis & COVID Impact 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 Gene Sequencing Definition In This Report 2.1.1 Gene Sequencing 2.1.2 Hereditary 2.1.3 Non Invasive Prenatal Testing 2.1.4 Oncology 2.1.5 Psychology 2.1.6 WGES 2.1.7 Pharmacogenomic 2.1.8 Direct to Consumer 2.1.9 Research 2.1.10 Other 2.2 The Genomics Revolution 2.3 Market Definition 2.3.1 Revenue Market Size 2.4 Methodology 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 2.6 Chromosomes, Genes and Epigenetics 2.6.1 Chromosomes 2.6.2 Genes 2.6.3 Epigenetics 2.6.4 Genetic Testing vs. Gene Sequencing 2.6.5 Cost and Pricing Practice 3 Global Listing of Sequencer Installed Base - Location & Contacts 3.1 Notes to Installed Base Listing 3.2 Illumina Installed Base 4 Market Overview 4.1 Players in a Dynamic Market 4.1.1 Academic Research Lab 4.1.2 Diagnostic Test Developer 4.1.3 Instrumentation Supplier 4.1.4 Chemical/Reagent Supplier 4.1.5 Pathology Supplier 4.1.6 Independent Clinical Laboratory 4.1.7 Public National/regional Laboratory 4.1.8 Hospital Laboratory 4.1.9 Physicians Office Lab (POLS) 4.1.10 Audit Body 4.1.11 Certification Body 4.2 Human Gene Sequencing -Markets, Examples and Discussion 4.2.1 Inherited Disease - Not what it used to be 4.2.1.1 Clinical and Research Lines Blur 4.2.1.2 Genetic Counselling - Not so simple anymore 4.2.1.3 The Genetic Blizzard - Issues of Access and Payment 4.2.2 Newborn Screening - The Standard of Care 4.2.2.1 Newborn Screening - Do Parents Want to Know? 4.2.3 NIPT - We've Only Just Begun 4.2.3.1 NIPT, IVF and the Fertility Practice - PGS, PGD, CCS 4.2.3.2 NIPT in the Future - Beyond Inherited Disease 4.2.4 Oncology - Understanding Two Worlds 4.2.4.1 The Tumor - A Sequence of Sequencing 4.2.4.2 The Tumor - Biopsy and Liquid Biopsy 4.2.4.3 The Human Genome - Predisposition and Prognosis 4.2.5 Pharmacogenomics 4.2.5.1 Sequencing Not the Only Player 4.2.5.2 New Roles for Old Drugs - A Research Bonanza? 4.2.6 Direct To Consumer - More Than Meets the Eye 4.2.6.1 DTC - How Many Segments? 4.3 Industry Structure 4.3.1 Hospital's Testing Share 4.3.2 The Rise of the Sequencing Lab 4.3.3 Sequencing as a Commodity 4.3.4 Informatics 4.3.5 Instrument Manufacturer Role 4.3.6 Healthcare Industry Impacts - Still Struggling 4.3.7 Can the Healthcare Industry Adapt? 4.3.8 Genetic Counselling as an Industry 4.3.9 Sequencing Adoption and Cannibalization 5 Market Trends 5.1 Factors Driving Growth 5.1.1 New Diagnoses 5.1.2 Wellness and Prevention 5.1.3 Fertility Technology 5.1.4 Cancer - Screening, Management and Monitoring 5.2 Factors Limiting Growth 5.2.1 Increased Competition Lowers Price 5.2.2 Lower Costs 5.2.3 Healthcare Cost Concerns Curtail Growth 5.2.4 Wellness has a downside 5.3 Sequencing Instrumentation 5.3.1 Instrumentation Tenacity 5.3.2 Declining Cost of Instruments Changes Industry Structure 5.3.3 Long Reads - Further Segmentation 5.3.4 Linked Reads 5.3.5 New Sequencing Technologies 6 Human Gene Sequencing Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.1.1 Importance of These Developments 6.1.2 How to Use This Section 6.2 Natera Files Suit Against NeoGenomics 6.3 Genomics England to Sequence 100K Newborns 6.4 Novigenix Raises $14M for NGS based Liquid Biopsy 6.5 LetsGetChecked Launching New PGx Service 6.6 Qiagen, Neuron23 Partner for NGS Diagnostic 6.7 Harbinger Health Technology Focused On Oncogenesis 6.8 Delfi Diagnostics to Develop Early Detection Test 6.9 Dante Labs to Introduce WGS to Italian Healthcare System 6.10 Invitae Neurodevelopmental Disorders Testing Service 6.11 Thermo Fisher Obtains CE Mark for Ion Torrent Genexus 6.12 Myriad Genetics Launches Suite of Cancer Tests 6.13 Oncocyte and Thermo Fisher Strike Partnership Deal 6.14 Illumina Partners With Precision Medicine to Assess Liquid Biopsy 6.15 Sysmex Inostics Develops Ultra-Sensitive Liquid Biopsy 6.16 Twist Bioscience, Centogene Partner on NGS-Based Rare Disease Testing 6.17 Strata Oncology Trial Supports NGS Assay 6.18 NYU Gets FDA Clearance for Sequencing Test 6.19 NeoGenomics to Acquire Inivata 6.20 OncoDNA, Institut Curie Partner on Liquid Biopsy Research 6.21 Cancer Heritability Gene Set Expanded 6.22 Whole-Genome Sequencing Could Replace Cytogenetics 6.23 Twist Bioscience, Berry Genomics Partner on Targeted NGS Assays 6.24 Ancestry Shutters Health Offering 6.25 Genetron Health Targeting Early Cancer Detection 6.26 Pan-European Initiative to Build Tools for Sharing Genomic Data 6.27 UK Government Unveils New Genomic Healthcare Strategy 6.28 Foundation Medicine Liquid Biopsy Gets FDA Approval 6.29 American Heart Association Develops Genetic Testing Guidelines 6.30 Yourgene Health Gets CE Mark for Iona NIPT Test 6.31 NorthShore Looks to Expand Genomics Integration Into Primary Care 6.32 Germline Results From Tumor Sequencing Guides Precision Therapy 6.33 FDA Clears Cancer Genomic Profiling From Personal Genome Diagnostics 6.34 BillionToOne Closes $15M Series A Follow-on Round 6.35 Clinics to Integrate Genomics Into Primary Care Appendices United States Medicare System: January 2022 laboratory Fees Schedule The Whole Genome Sequence of SARS-CoV-2 Profiles of Key Companies 10x Genomics, Inc. 23andME Inc. Abbott Laboratories AccuraGen Inc. Adaptive Biotechnologies Admera Health, LLC Agilent/Dako Akonni Biosystems Amoy Diagnostics Co., Ltd. Ancestry.com LLC Anchor Dx Arc Bio Arrayit Corporation ARUP Laboratories Astrid Bio Baylor Miraca Genetics Laboratories Beckman Coulter Diagnostics Becton, Dickinson and Company BGI Genomics Co. Ltd Bioarray Genetics Biocept, Inc. Biodesix Inc. BioFluidica BioGenex Biolidics Ltd bioMerieux Diagnostics Bioneer Corporation Bio-Rad Laboratories, Inc. Bio-Techne C2i Genomics Caris Molecular Diagnostics CellMax Life Centogene Cepheid (Danaher) Circulogene Clinical Genomics Color Genomics Complete Genomics, Inc. - A BGI Company Dante Labs Datar Cancer Genetics Limited Diasorin S.p.A. Element Biosciences Epic Sciences Epigenomics AG Eurofins Scientific Excellerate Bioscience Fabric Genomics Freenome FUJIFILM Wako Diagnostics Fujirebio Fulgent Genetics GE Global Research Gene by Gene, Ltd. Genedrive GeneFirst Ltd. Genetron Holdings Genewiz Genomics England Genomics Personalized Health (GPH) GenomOncology Genzyme Corporation Grifols Guardant Health Guardiome HeiScreen Helix Helomics Hologic HTG Molecular Diagnostics Human Longevity, Inc. iCellate Illumina Incell Dx Inivata Integrated Diagnostics Invitae Corporation Invivoscribe Karius Letsgetchecked Lexagene Lunglife AI Inc Macrogen MDNA Life SCIENCES, Inc. MDx Health Medgenome Meridian Bioscience Mesa Biotech (Thermo Fisher) Mesa Laboratories, Inc. miR Scientific MNG Labs NantHealth, Inc. Natera Nebula Genomics 448 NeoGenomics New England Biolabs, Inc. NGeneBio Novogene Bioinformatics Technology Co., Ltd. Omega Bioservices Oncocyte OncoDNA OpGen ORIG3N, Inc. Origene Technologies Oxford Nanopore Technologies Panagene Perkin Elmer Personal Genome Diagnostics Personalis Precipio PrecisionMed Promega Protagen Diagnostics Qiagen QuantuMDx Regeneron Pharmaceuticals Roche Molecular Diagnostics Roswell Biotechnologies Seegene SeLux Diagnostics Sema4 Holdings Sequencing.com Siemens Healthineers simfo GmbH Singlera Genomics Inc. Singular Genomics SkylineDx Standard BioTools Sure Genomics, Inc. Sysmex Sysmex Inostics Tempus Labs, Inc. Thermo Fisher Scientific Inc. Ultima Genomics Variantyx Volition Vyant Bio For more information about this report visit https://www.researchandmarkets.com/r/nqo2do About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The "Genetic Testing Markets. Global Market Analysis with Forecasts by Applications, Technologies, Products and Users with Executive and Consultant Guides 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Unlimited growth potential? Genetic Testing has crossed the chasm and is now growing in every area. What are the opportunities? What are the pitfalls? The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life, and new problems for the industry. The report includes detailed breakouts for 14 countries and 5 regions. Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years. This research makes you the expert in your organization. Make investment decisions and valuations with confidence using the latest data. Key Topics Covered: 1 Market Guides 1.1 Genetic Testing - Strategic Situation Analysis & Company Rankings 1.1.1 Selected Genetic Testing Companies Revenue & Growth 1.1.2 Selected Companies Growth Chart 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 Genetic Testing Definition in This Report 2.2 The Genomics Revolution 2.3 Market Definition 2.3.1 Revenue Market Size 2.3.2 Newborn Screening 2.3.3 Non Invasive Pregnancy Testing 2.3.4 Predictive 2.3.5 Oncology 2.3.6 Direct to Consumer 2.3.7 Other Application 2.3.8 PCR 2.3.9 NGS 2.3.10 Cytogenetic 2.3.11 Other Technology 2.4 Methodology 2.4.1 Methodology 2.4.2 Sources 2.4.3 Authors 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 2.6 Chromosomes, Genes and Epigenetics 2.6.1 Chromosomes 2.6.2 Genes 2.6.3 Epigenetics 3 Market Overview 3.1 Players in a Dynamic Market 3.1.1 Academic Research Lab 3.1.2 Diagnostic Test Developer 3.1.3 Instrumentation Supplier 3.1.4 Chemical/Reagent Supplier 3.1.5 Pathology Supplier 3.1.6 Independent Clinical Laboratory 3.1.7 Public National/regional Laboratory 3.1.8 Hospital Laboratory 3.1.9 Physicians Office Lab (POLS) 3.1.10 Audit Body 3.1.11 Certification Body 3.2 Genetic Tests - Types, Examples and Discussion 3.2.1 Preimplantation Genetic Diagnosis - An Emerging Market 3.2.2 Prenatal Diagnosis - New Technologies Create Opportunity 3.2.3 Newborn Screening 3.2.4 Diagnostic Testing 3.2.5 Carrier Testing 3.2.6 Predictive and Presymptomatic Testing 3.2.7 Pharmacogenomics 3.2.8 Forensic Testing 3.2.9 Parental Testing 3.2.10 Ancestral Testing 3.3 Industry Structure 3.3.1 Hospital's Testing Share 3.3.2 Economies of Scale 3.3.3 Hospital vs. Central Lab 3.3.4 Physician Office Lab's 3.3.5 Physician's and POCT 4 Market Trends 4.1 Factors Driving Growth 4.1.1 Genetic Discoveries Creating New Diagnostic Markets 4.1.2 The Aging Effect 4.1.3 Pharmacogenomics Drives Further Growth 4.1.4 Oncology and Liquid Biopsy Enter New Era 4.1.5 Fertility Practice Growth drives market 4.1.6 Direct to Consumer begins to break out 4.2 Factors Limiting Growth 4.2.1 Increased Competition Lowers Price 4.2.2 Lower Costs 4.2.3 Testing usage analysis curtailing growth 4.2.4 Wellness has a downside 4.3 Instrumentation, Automation and Diagnostic Trends 4.3.1 Traditional Automation and Centralization 4.3.2 The New Automation, Decentralization and Point of Care 4.3.3 Instruments Key to Market Share 4.3.4 Bioinformatics Plays a Role 4.3.5 PCR Takes Command 4.3.6 Next Generation Sequencing Fuels a Revolution 4.3.7 NGS Impact on Pricing 4.3.8 Whole Genome Sequencing, A Brave New World 4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 4.3.10 Shifting Role of Diagnostics 5 Genetic Testing Recent Developments 5.1 Recent Developments 5.1.1 Importance of This Section 5.1.2 How to Use This Section 5.2 Novitas Rescinds Coverage for Multiple Genetic Tests 5.3 PerkinElmer (now Revvity) Becomes Dx Life Science Firm 5.4 New POC Genotyping Tests Based on Electromagnetic Detection 5.5 GenoMe Dx Launching dPCR Cancer Test 5.6 mDetect To Trial Breast Cancer Liquid Biopsy 5.7 Genomics England, Aims to Sequence 100K Newborns 5.8 Juno Diagnostics NIPT With At-Home Sample Collection 5.9 Cardio Diagnostics Launches Genetic Cario Risk Test 5.10 Universal Genetic Testing in Breast Cancer Further Supported 5.11 Aniling Gets CE-IVD Marks for Cancer Sequencing Tests 5.12 MyOme Lands Investment for WGS 5.13 Type 2 Diabetes GWAS Enables Risk Prediction 5.14 LetsGetChecked to Acquire Veritas Genetics 5.15 Guardant Health Plans New Comprehensive Assay 5.16 Tesis Labs Raises $20M 5.17 Sema4: Sema4 Elements 5.18 Clarified Precision Medicine Acquires Interpares Biomedicine 5.19 Genetic Technologies to Acquire DTC Genetic Test Provider EasyDNA 5.20 Illumina, Belgium Genetic Centers Partner on WGS-Based Dx 6 Profiles of Key Companies 6.1 10x Genomics, Inc. 6.2 23andME Inc. 6.3 Abbott Laboratories 6.4 Adaptive Biotechnologies 6.5 Admera Health, LLC 6.6 Agilent/Dako 6.7 Akonni Biosystems 6.8 Amoy Diagnostics Co., Ltd. 6.9 Ancestry.com LLC 6.10 Anchor Dx 6.11 Arc Bio 6.12 Arrayit Corporation 6.13 ARUP Laboratories 6.14 Aus Diagnostics 6.15 BaseClear 6.16 Baylor Miraca Genetics Laboratories 6.17 Beckman Coulter Diagnostics 6.18 Becton, Dickinson and Company 6.19 BGI Genomics Co. Ltd 6.20 Bioarray Genetics 6.21 Biocept, Inc. 6.22 Biodesix Inc. 6.23 BioFluidica 6.24 BioGenex 6.25 Biolidics Ltd 6.26 bioMerieux Diagnostics 6.27 Bioneer Corporation 6.28 Bio-Rad Laboratories, Inc 6.29 Bio-Techne 6.30 C2i Genomics 6.31 CareDx 6.32 Caris Molecular Diagnostics 6.33 CellMax Life 6.34 Centogene 6.35 Cepheid (Danaher) 6.36 Circulogene 6.37 Clinical Genomics 6.38 Color Genomics 6.39 Complete Genomics, Inc. - A BGI Company 6.40 CosmosID 6.41 Dante Labs. 6.42 Datar Cancer Genetics Limited 6.43 Diasorin S.p.A. 6.44 Element Biosciences 6.45 Element Biosciences 6.46 Epic Sciences 6.47 Epigenomics AG. 6.48 Eurofins Scientific 6.49 Excellerate Bioscience 6.50 Fabric Genomics 6.51 Freenome 6.52 Fujirebio 6.53 Fulgent Genetics 6.54 Gene by Gene, Ltd. 6.55 Genedrive 6.56 GeneFirst Ltd. 6.57 Genetron Holdings 6.58 Genomics England 6.59 Genomics Personalized Health (GPH) 6.60 GenomOncology 6.61 Genzyme Corporation 6.62 Grifols 6.63 Guardant Health 6.64 Guardiome 6.65 HeiScreen 6.66 Helix 6.67 Helix OpCo 6.68 Helomics 6.69 Hologic 6.70 HTG Molecular Diagnostics 6.71 Human Longevity, Inc. 6.72 iCellate 6.73 Illumina 6.74 Incell Dx 6.75 Inivata 6.76 Integrated Diagnostics 6.77 Invitae Corporation 7 Global Market Size 7.1 Global Market by Country 7.2 Global Market by Application 7.3 Global Market by Technology 7.4 Global Market by Product 7.5 Global Market by User 8 Market Sizes by Application 8.1 Newborn Testing Market 8.2 NIPT Market 8.3 Predictive Testing Market 8.4 Oncology Testing Market 8.5 DTC Testing Market 9 Global Genetic Testing Market by Technology 9.1 PCR Testing Market 9.2 NGS Market 9.3 Cytogenetic Testing Market 10 Global Genetic Testing Market by Product 10.1 Instruments Market 10.2 Reagents and Kits Market 10.3 Software Market 10.4 Services Market 11 Global Genetic Testing Market by User 11.1 Academic Market 11.2 Clinical Market 11.3 Pharmaceutical Market 11.4 Industrial and Other Market 12 The Future of Genetic Testing 13 Appendices 13.1 United States Medicare System: Laboratory Fees Schedule 13.2 The Most Used IVD Assays 13.3 The Highest Grossing Assays For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets